Evidence map›Paper›PMID 42306882›Full record

ArticleInfluenza and other respiratory viruses2026

Reduction in Respiratory Syncytial Virus (RSV)-Related Outpatient and Inpatient Cases Among Infants During the Initial 2024/2025 Season Following Nirsevimab Recommendation in Germany.

Wei Cai, Isabelle Maronde, Sophie Köndgen, Barbara Biere, Silke Buda, Brunhilde Schweiger, Doreen Staat, Walter Haas, Ekkehard Schuler, Virologic SARI Surveillance Study Group and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Influenza and other respiratory viruses, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Wei CaiUnit 36, Respiratory Infections, Department of Infectious Disease Epidemiology, Robert Koch Institute, Berlin, Germany.ORCID https://orcid.org/0000-0001-8650-4880
Isabelle MarondeUnit 17, Influenza and Other Respiratory Viruses, Department of Infectious Diseases, National Influenza Centre, Robert Koch Institute, Berlin, Germany.ORCID https://orcid.org/0009-0001-7382-8816
Sophie KöndgenUnit 17, Influenza and Other Respiratory Viruses, Department of Infectious Diseases, National Influenza Centre, Robert Koch Institute, Berlin, Germany.ORCID https://orcid.org/0000-0001-5107-8033
Barbara BiereUnit 17, Influenza and Other Respiratory Viruses, Department of Infectious Diseases, National Influenza Centre, Robert Koch Institute, Berlin, Germany.ORCID https://orcid.org/0000-0001-6988-3735
Silke BudaDepartment of Infectious Disease Epidemiology, Robert Koch Institute, Berlin, Germany.ORCID https://orcid.org/0000-0003-3448-3357
Brunhilde SchweigerUnit 17, Influenza and Other Respiratory Viruses, Department of Infectious Diseases, National Influenza Centre, Robert Koch Institute, Berlin, Germany.ORCID https://orcid.org/0000-0003-4847-9199
Doreen StaatUnit 36, Respiratory Infections, Department of Infectious Disease Epidemiology, Robert Koch Institute, Berlin, Germany.ORCID https://orcid.org/0009-0003-4652-7537
Walter HaasUnit 36, Respiratory Infections, Department of Infectious Disease Epidemiology, Robert Koch Institute, Berlin, Germany.
Ekkehard SchulerHELIOS KLINIKEN GmbH, Berlin, Germany.
Virologic SARI Surveillance Study Group
Thorsten WolffUnit 17, Influenza and Other Respiratory Viruses, Department of Infectious Diseases, National Influenza Centre, Robert Koch Institute, Berlin, Germany.ORCID https://orcid.org/0000-0001-7688-236X
Ralf DürrwaldUnit 17, Influenza and Other Respiratory Viruses, Department of Infectious Diseases, National Influenza Centre, Robert Koch Institute, Berlin, Germany.ORCID https://orcid.org/0000-0002-3432-0438
Djin-Ye OhUnit 17, Influenza and Other Respiratory Viruses, Department of Infectious Diseases, National Influenza Centre, Robert Koch Institute, Berlin, Germany.ORCID https://orcid.org/0000-0003-0541-6155
Kristin TolksdorfUnit 36, Respiratory Infections, Department of Infectious Disease Epidemiology, Robert Koch Institute, Berlin, Germany.ORCID https://orcid.org/0000-0002-8712-6399
Janine ReicheUnit 17, Influenza and Other Respiratory Viruses, Department of Infectious Diseases, National Influenza Centre, Robert Koch Institute, Berlin, Germany.ORCID https://orcid.org/0000-0003-2541-1095

Funding

Bundesministerium für Gesundheit D82015European Centre for Disease Prevention and Control 2021/PHF/23776Robert Koch Institut 911227Vaccine effectiveness, burden and impact studies VEBISLOT1SC5Vaccine effectiveness, burden and impact studies VEBISLOT1SC8Vaccine effectiveness, burden and impact studies VEBISLOT5SC4Vaccine effectiveness, burden and impact studies VEBISLOT5SC5
6 · The paper itself

Abstract

After introducing nirsevimab during the 2024/2025 respiratory syncytial virus (RSV) season in Germany, RSV activity in infants under 1 year dropped by 50% in primary care and 50%-70% in secondary care. Inpatients under 6 months showed the greatest reduction. RSV severity decreased with fewer RSV-associated ICU admissions and shorter hospital stays. RSV sequence analysis identified four known polymorphisms in the nirsevimab binding site among inpatients; none associated with resistance. These findings indicate that nirsevimab effectively reduced medically attended RSV disease in infants.

Indexed as

Antiviral AgentsRespiratory Syncytial Virus, HumanRespiratory Syncytial Virus InfectionsFemaleGermanyHospitalizationHumansInfantInpatientsOutpatientsSeasonsAntiviral Agentsdisease severityhospitalisedinfantsnirsevimaboutpatientresistant mutationsrespiratory syncytial virussurveillance

Identifiers

PMID42306882
PMCPMC13273525

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.